Assetmark Inc. Increases Stake in Sanofi $SNY

Assetmark Inc. boosted its stake in shares of Sanofi (NASDAQ:SNY) by 25.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 357,172 shares of the company’s stock after purchasing an additional 71,356 shares during the period. Assetmark Inc.’s holdings in Sanofi were worth $16,859,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Wedbush Securities Inc. increased its position in shares of Sanofi by 7.3% in the 3rd quarter. Wedbush Securities Inc. now owns 11,598 shares of the company’s stock valued at $547,000 after acquiring an additional 792 shares during the period. Cibc World Market Inc. increased its holdings in shares of Sanofi by 4.0% in the third quarter. Cibc World Market Inc. now owns 374,816 shares of the company’s stock valued at $17,691,000 after purchasing an additional 14,325 shares during the period. Caprock Group LLC purchased a new position in shares of Sanofi in the third quarter worth about $1,347,000. Stratos Wealth Partners LTD. acquired a new stake in shares of Sanofi during the third quarter worth about $634,000. Finally, Providence Capital Advisors LLC boosted its position in Sanofi by 2.7% in the third quarter. Providence Capital Advisors LLC now owns 58,806 shares of the company’s stock valued at $2,776,000 after buying an additional 1,554 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Trending Headlines about Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Sanofi Trading Down 2.2%

Shares of NASDAQ:SNY opened at $46.01 on Friday. The business’s 50 day moving average price is $47.73 and its 200-day moving average price is $48.59. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The firm has a market capitalization of $112.22 billion, a price-to-earnings ratio of 12.78, a price-to-earnings-growth ratio of 1.20 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.29.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SNY shares. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Citigroup began coverage on shares of Sanofi in a report on Tuesday, January 27th. They set a “neutral” rating for the company. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Finally, Guggenheim downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.